Description

BRILINTA 90 MG (1X14)

Indications

BRILINTA (ticagrelor) is an antiplatelet medication indicated for the prevention of cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). It is used in conjunction with aspirin to reduce the risk of thrombotic cardiovascular events such as heart attacks and strokes. BRILINTA is particularly beneficial for patients who have experienced a heart attack or unstable angina, as it helps to prevent the formation of blood clots that can lead to further complications.

Mechanism of Action

BRILINTA functions as a reversible inhibitor of the P2Y12 component of the ADP receptor on platelets. By blocking this receptor, BRILINTA prevents ADP-mediated activation of the glycoprotein IIb/IIIa complex, which is crucial for platelet aggregation. This action reduces the likelihood of platelet clumping and subsequent thrombus formation, thereby decreasing the risk of cardiovascular events. Unlike clopidogrel, another antiplatelet agent, BRILINTA has a faster onset of action and does not require metabolic activation, which contributes to its efficacy in acute settings.

Pharmacological Properties

BRILINTA is characterized by its rapid absorption and onset of action. After oral administration, peak plasma concentrations are reached within 1.5 hours. The bioavailability of ticagrelor is approximately 36%, and it is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, particularly CYP3A4 and CYP3A5. The elimination half-life of ticagrelor is approximately 7 hours, and its active metabolite also contributes to its antiplatelet effects. The drug is primarily excreted via the feces, with a minor portion eliminated through the urine.

Contraindications

BRILINTA is contraindicated in patients with a history of hypersensitivity to ticagrelor or any of its components. It should not be used in patients with active bleeding, such as gastrointestinal bleeding or intracranial hemorrhage, as well as in those with a history of severe hepatic impairment. Additionally, BRILINTA is contraindicated in patients who are undergoing surgery that requires cessation of antiplatelet therapy, as the risk of bleeding may outweigh the benefits of continued treatment.

Side Effects

The most common side effects associated with BRILINTA include bleeding events, which can range from minor bruising to more serious complications such as gastrointestinal bleeding or intracranial hemorrhage. Other reported side effects include dyspnea (shortness of breath), headache, dizziness, and nausea. Patients should be monitored for signs of bleeding, and any unusual symptoms should be reported to a healthcare provider immediately. In rare cases, hypersensitivity reactions may occur, necessitating discontinuation of the medication.

Dosage and Administration

The standard initial dose of BRILINTA is 180 mg, followed by a maintenance dose of 90 mg twice daily. It is recommended to administer BRILINTA with or without food, as food does not significantly affect its absorption. Patients should be advised to take the medication consistently at the same times each day to maintain stable blood levels. It is essential to continue aspirin therapy at a low dose (75-100 mg daily) while on BRILINTA, as the combination therapy has been shown to enhance the antiplatelet effect and reduce the risk of cardiovascular events.

Interactions

BRILINTA is known to interact with several medications, particularly those that inhibit or induce CYP3A4. Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, and ritonavir can increase the plasma concentrations of ticagrelor, leading to an increased risk of bleeding. Conversely, strong CYP3A4 inducers like rifampin can decrease ticagrelor levels, reducing its efficacy. Therefore, it is crucial for healthcare providers to review a patient’s medication list for potential interactions and adjust therapy as necessary. Additionally, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) should be approached with caution due to the increased risk of gastrointestinal bleeding.

Precautions

Before initiating treatment with BRILINTA, healthcare providers should conduct a thorough assessment of the patient’s medical history, particularly regarding bleeding disorders, recent surgeries, and liver function. Patients with a history of asthma or chronic obstructive pulmonary disease (COPD) should be monitored closely for respiratory symptoms, as BRILINTA can cause dyspnea in some individuals. Regular follow-up appointments are recommended to assess the effectiveness of the therapy and to monitor for any adverse effects. Patients should be educated about the signs and symptoms of bleeding and advised to seek medical attention if they experience any unusual bruising, prolonged bleeding, or other concerning symptoms.

Clinical Studies

BRILINTA has been evaluated in several pivotal clinical trials, most notably the PLATO (Platelet Inhibition and Patient Outcomes) trial. This large-scale study demonstrated that BRILINTA significantly reduced the incidence of cardiovascular death, heart attack, and stroke compared to clopidogrel in patients with ACS. The trial included a diverse population and provided robust evidence supporting the use of BRILINTA as a first-line antiplatelet agent in this patient group. Further studies have confirmed the safety and efficacy of BRILINTA in various clinical settings, reinforcing its role in the management of patients at high risk for thrombotic events.

Conclusion

BRILINTA 90 mg is an effective antiplatelet medication that plays a crucial role in the prevention of cardiovascular events in patients with acute coronary syndrome and a history of myocardial infarction. Its unique mechanism of action, rapid onset, and proven efficacy make it a valuable option for clinicians managing patients at risk for thrombotic complications. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective treatment. Ongoing monitoring and patient education are vital components of successful therapy with BRILINTA.